Bis 94
Alternative Names: Bis-94Latest Information Update: 21 Jul 2023
At a glance
- Originator L and L Biopharma
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Jul 2023 Preclinical trials in Cancer in China (Parenteral) (L and L Biopharma pipeline, July 2023)